Edwards Lifesciences (NYSE: EW) insider files Form 144 to sell 5,487 shares

Rhea-AI Filing Summary

Edwards Lifesciences executive plans modest stock sale under Rule 144. A notice was filed for the proposed sale of 5,487 shares of Edwards Lifesciences common stock through broker Charles Schwab & Co., Inc. on or about 12/12/2025 on the NYSE. The shares have an aggregate market value of $459,682.00 based on the price used in the notice, compared with 580,300,000 Edwards Lifesciences shares stated as outstanding.

The seller acquired these 5,487 shares on 05/08/2023 as equity compensation via RSU/PSU awards from Edwards Lifesciences Corporation. The filing also reports that, over the prior three months, the same individual sold 11,340 Edwards Lifesciences shares on 12/10/2025 for gross proceeds of $950,582.00. The signer confirms they are not aware of undisclosed material adverse information about the company’s operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	5487	459682.00	580300000	12/12/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/08/2023	RSU / PSU - See Remarks	EDWARDS LIFESCIENCES CORPORATION			5487	05/08/2023	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
DONALD E BOBO JR ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	12/10/2025	11340	950582.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does this Form 144 filing mean for Edwards Lifesciences (EW)?

This Form 144 notice shows an Edwards Lifesciences insider intends to sell 5,487 common shares on or about 12/12/2025 under Rule 144. It is a disclosure of a planned sale, not a change to the company’s operations or capital structure.

How many Edwards Lifesciences (EW) shares are being proposed for sale?

The notice covers a proposed sale of 5,487 shares of Edwards Lifesciences common stock, with an aggregate market value of $459,682.00 based on the price referenced in the filing.

Who is selling shares of Edwards Lifesciences (EW) in this Form 144?

The seller is identified as Donald E. Bobo Jr., who is associated with Edwards Lifesciences and whose address is listed as One Edwards Way, Irvine, CA 92614. The shares were received as equity compensation from Edwards Lifesciences Corporation.

How were the Edwards Lifesciences (EW) shares being sold originally acquired?

The 5,487 shares proposed for sale were acquired on 05/08/2023 as RSU/PSU equity compensation from Edwards Lifesciences Corporation, with the nature of payment described as equity compensation rather than a cash purchase.

Has this Edwards Lifesciences (EW) insider sold other shares recently?

Yes. The filing reports that over the past three months, the same seller disposed of 11,340 Edwards Lifesciences shares on 12/10/2025, generating gross proceeds of $950,582.00.

How large is the planned Edwards Lifesciences (EW) sale compared to shares outstanding?

The notice states there are 580,300,000 Edwards Lifesciences shares outstanding. The proposed sale of 5,487 shares is a very small fraction of this baseline figure.

What assurances does the Edwards Lifesciences (EW) seller give in this notice?

By signing the notice, the seller represents that they do not know any material adverse information about Edwards Lifesciences’ current or prospective operations that has not been publicly disclosed, in line with Rule 144 requirements.